Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL402 booster immunogenicity and safety study in adolescents and adults
jRCT2031240386Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of CSL402 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoints: Geometric mean titer of neutralizing antibodies against SARS-CoV-2 (Omicron JN.1) on Day 29 and Non-inferiority of immunogenicity in children versus adults. Started Oct 2024; status: completed.
02
Drugs
CSL402
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031240386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240386.